528283
Polo-like Kinase Inhibitor II, BTO-1
5-Cyano-7-nitro-2-(benzothiazolo-N-oxide)-carboxamide
Para preguntas en general por favor contacte a nuestro Servicio de Atención al Cliente:
Merck KGaA
Frankfurter Str. 250
64293 Darmstadt
Germany
Teléfono: +49 6151 72-0
Fax: +49 6151 72 2000
01 junio 2012
cargando
A cell-permeable benzothiazolo-N-oxide compound that targets the ATP-binding pocket of polo-like kinase and is shown to inhibit Plk1 kinase activity in cell-free kinase assays (IC50 = 8.0 µM) and suppress the phosphorylation of cellular Plk1 substrate Cdc25C in rat kangaroo kidney-derived PTK cells (75% inhibition at 6.3 µM). BTO-1 treatment of cultured cells results in mitosis defects consistent with loss-of-Plk1 phenotypes seen in Plk1 RNAi-treated U20S cells, including the appearance of monopolar spindles and the reduction of γ-tubulin at the centrosomes. Plk1 inhibition by BTO-1 in HeLa cells results in a blockage of Rho and Rho-GEF recruitment, which is essential for the assembly of a functional contractile ring.
| Información sobre producto | |||
|---|---|---|---|
| Form | Beige solid | ||
| Protect from Light | Si | ||
| Packaged under inert gas | Si | ||
| Purity | ≥97% by HPLC | ||
| Fórmula químico | C9H4N4O4S | ||
| Número CAS | 40647-02-7 | ||
| Almacenar y enviar información | |||
|---|---|---|---|
| Categoría de alamacenamiento | +2°C to +8°C | ||
| Ship |
Ambient Temperature Only
Harmful |
||
| Información de seguridad | |||
|---|---|---|---|
| Frase S |
S: 26-36/37 |
||
| Frase R |
R: 20/21/22-36/37/38 |
||
